Table 1-.
Demographic and clinical characteristics of study participants.
| Variables | No Azithromycin (n=14) | Azithromycin (n=12) | p-value |
|---|---|---|---|
| Age (years)a | 32.14 (3.92) | 35.25 (4.67) | 0.08 |
| BMI (kg/m2)a | 31.53 (8) | 30.48 (7) | 0.73 |
| Tobacco Use | 0 | 0 | - |
| AMH (ng/mL)a | 2.29 (1.06) | 1.47 (0.62) | 0.03 |
| AFCb | 32 (18, 50) | 24 (13, 39) | 0.31 |
| Race | 1.00 | ||
| - White | 13 (92.9%) | 12 (100%) | |
| - Asian | 1 (7.1%) | 0 (0%) | |
| Ethnicity | 1.00 | ||
| - Non-Hispanic | 14 (100%) | 12 (100%) | |
| Duration of Infertility (months)b | 25 (18, 48) | 18 (8, 32) | 0.15 |
| Diagnosis | 0.20 | ||
| - Male Factor | 5 (35.7%) | 3 (25%) | |
| - Unexplained | 1 (7.1%) | 4 (33.3%) | |
| - Tubal Factor | 2 (14.3%) | 1 (8.3%) | |
| - Endometriosis | 1 (7.1%) | 1 (8.3%) | |
| - Ovulatory Dysfunction | 1 (7.1%) | 1 (8.3%) | |
| - PCOS | |||
| - DOR | 4 (28.6%) | 0 (0%) | |
| 0 (0%) | 2 (16.7%) | ||
| Protocol | 0.03 | ||
| - Long Agonist | 9 (64.3%) | 7 (58.3%) | |
| - Antagonist | 5 (35.7%) | 1 (8.3%) | |
| - Flare | 0 (0%) | 4 (33.3%) | |
| Prior Live Birth | 1.0 | ||
| - Yes | 3 (21.4%) | 2 (16.7%) | |
| - No | 11 (78.6%) | 10 (83.3%) |
BMI, body mass index.
AMH, antimullerian hormone.
AFC, antral follicle count.
PCOS, polycystic ovarian syndrome.
DOR, diminished ovarian reserve.
a
Mean ± standard deviation
b
Median (interquartile range)